TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03136627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
Study: NCT02143245

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Synovial Biopsy
Description: Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
Study: NCT01400828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: 5 mg (encapsulated) tablets QD/14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (encapsulated) Tablets QD/14 days
Study: NCT03792711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure® Plus Advance
Description: Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women.
Study: NCT01945892

Intervention type: DRUG
Intervention: Ozurdex
Description: - Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior.
Study: NCT04029337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Description: Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
Study: NCT00982605

Intervention type: PROCEDURE
Intervention: EBUS_TBNA
Description: EBUS during bronchoscopy
Study: NCT00827489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTC-867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01241786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 IV or SC D 1-5
Study: NCT02750410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00940706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TreadMill
Description: Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity in groups
Description: Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring physical activity
Description: Activity monitoring with accelerometers
Study: NCT03950323

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI with Facial nerve tractography
Description: MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
Study: NCT05780281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831
Description: VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT00378729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and FSHr
Description: treatment for infertility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian drilling by FERTILOSCOPY
Description: surgical ovarian drilling
Study: NCT02957708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mCIMT + SR
Description: Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance.
Study: NCT03877796

Intervention type: DEVICE
Intervention: Drug Response Predictor® (DRP)
Description: A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
Study: NCT02957708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
Study: NCT02952716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cord blood mononuclear cell
Description: The patients were treated by human cord blood mononuclear cell through subarachnoid space

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric oxygen
Description: The patients were treated by hyperbaric oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The patients were treated by hyperbaric oxygen
Study: NCT02143245

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Open Tissue Biopsy
Description: During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
Study: NCT00628810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT00634673

Intervention type: OTHER
Group type: OTHER
Intervention: sandwich
Description: standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
Study: NCT01281891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIA
Description: Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
Study: NCT01281891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I/T morphine
Description: Morphine special 0.1 mg injected intrathecally
Study: NCT02424149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Study: NCT02838160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: After baseline measurement, Group 1 did not receive any intervention or education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: After baseline measurement, Group 1 did not receive any intervention or education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: After baseline measurement, Group 1 did not receive any intervention or education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet
Description: Group 2 received only the designed booklet without any participation in the oral presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet
Description: Group 2 received only the designed booklet without any participation in the oral presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet
Description: Group 2 received only the designed booklet without any participation in the oral presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet Plus participation in oral presentations
Description: Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet Plus participation in oral presentations
Description: Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside
Description: The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
Study: NCT03306030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose of 4L PEG
Description: All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three times dose of 4L PEG
Description: The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
Study: NCT02856386

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenol supplement
Description: 8 mL once daily
Study: NCT03302780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.
Study: NCT03952286

Intervention type: DRUG
Group type: OTHER
Intervention: ED-Dispensing home and school supervision
Description: 1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-Dispensing home and school supervision
Description: 1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms.
Study: NCT03302780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS active
Description: tDCS will be applied for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS sham
Study: NCT02375386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic touch
Description: Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Both groups will receive an fMRI.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fMRI
Description: Both groups will receive an fMRI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Sensitivity Testing
Description: Both groups will receive an Pain Sensitivity Testing

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pain Sensitivity Testing
Description: Both groups will receive an Pain Sensitivity Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Both groups will receive Questionnaires

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Description: Both groups will receive Questionnaires
Study: NCT04177030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isopesticide dietary scheme
Description: All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isopesticide dietary scheme
Description: All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met.
Study: NCT02375386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Impairment
Description: Both groups will receive testing on physical impairment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physical Impairment
Description: Both groups will receive testing on physical impairment.
Study: NCT01608269

Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir/Lamivudine
Description: one tablet once a day
Study: NCT01093989

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate Syrup
Description: Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulphate Syrup
Description: Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
Study: NCT00699296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: 20mg/day p.o. on three times-a- week
Study: NCT01208337

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab
Description: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
Study: NCT02535611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Beside the usual treatment for ischemic stroke this group will be treated by memantine.
Study: NCT02910778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
Study: NCT00309101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study: NCT02910778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Study: NCT04990570

Intervention type: OTHER
Intervention: Telemedicine in the form Virtual clinic via video consultation
Description: Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter.
Study: NCT02175550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NR CC
Study: NCT00631319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Description: hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05505058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual material
Description: Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-visual material
Description: Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
Study: NCT01165229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection.